New drug plus BCG vs chemo for BCG-resistant bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of bladder cancer called high-risk non-muscle invasive bladder cancer that did not respond to BCG treatment.
- You are not able to or choose not to have your bladder removed (radical cystectomy).
- You have good kidney, liver, and blood cell function.
- You have not had immunotherapy or certain other treatments for your bladder cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two investigational drugs given together to treat high-risk non-muscle invasive bladder cancer that cannot be completely removed with standard surgery. The goal is to see if this combination can help control the cancer and avoid the need for bladder removal.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.